



## Mapping REDCap Data into SDTM: A Case Study of Healthy Volunteer Research Data

Presented by Susan Mutter, Director, Statistical Programming,  
PROMETRIKA, LLC



# Meet the Speaker

Susan Mutter

**Title:** Director, Statistical Programming

**Organization:** PROMETRIKA, LLC

Susan has more than 25 years of diverse experience in clinical database design and management, and statistical programming. She has shared her extensive knowledge of CDISC and SDTM at conferences and training programs in the US, Russia, Europe and Asia. Earlier in her career, Susan participated as a research associate and data analyst for several projects sponsored by the US Military and NASA. She has co-authored several journal articles on nutrition in military field situations. Susan received her Bachelor of Arts in Psychobiology from Mount Holyoke College and is a member of the CDISC Advisory Council Task Force.



# Disclaimer and Disclosures

- *The views and opinions expressed in this presentation are those of the author and do not necessarily reflect the official policy or position of CDISC.*
- *The author has no real or apparent conflicts of interest to report.*



# Agenda

1. Introduction
2. What is REDCap and how is it related to CDISC?
3. Details on the Case Study
4. Mapping the Data
5. Conclusions

# Introduction



# Introduction

- Have you heard of REDCap?
- Have you used the REDCap interface?
- Have you worked with data from REDCap?



# What is REDCap and how is it related to CDISC?



# What is REDCap and how is it related to CDISC?

## Research Electronic Data Capture (REDCap)

- Developed at Vanderbilt University (Nashville, Tennessee, USA)
- A free, user-friendly web-based interface which requires no background knowledge or technical experience to use
- Made available for use exclusively to non-profit institutions

As of April 2025, the REDCap Consortium consists of:

- 7760 institutions
- 160 countries
- 2.3 million projects
- 3.7 million users
- 45,300 citations
- Potential for a huge pool of data that pharma could tap into (e.g. Natural History)



# What is REDCap and how is it related to CDISC? - 2

Googling for “REDCap to CDISC SDTM”, etc. doesn’t generate a lot of hits

- Challenges of Academia Using CDISC Standards\*
  - Regardless of the human study research topic, many data points are easily standardized
  - Data points that are difficult to standardize are also the items where SDTM mapping is difficult and therefore advanced CDISC education is needed
  - Money and time budgets are needed for training
  - Many institutions have short term contracts (<5 years), so most personnel will be leaving/graduating, right when they become experts

\*A use-case analysis of Clinical Data Interchange Standards Consortium/Study Data Tabulation Model in academia in an investigator-initiated clinical trial Nagoya J. Med. Sci. 84. 120–132, 2022

# What is REDCap and how is it related to CDISC? - 3

- CDISC Real World Data Connect project recommendations\*
  - Make CDISC standards easier to use in settings outside clinical research for regulatory submission
  - Take steps to support academic and public health researchers in the use of data coming from observational studies and registries
    - CDISC Translated metadata from 34 CDASH Foundational eCRFs and 20 CDASH Crohn's Disease eCRFs into REDCap eCRF metadata\*\*
      - Searching for “CDASH”, “CDISC”, etc. in REDCap yields nothing
      - Possible to find the forms by searching for “REDCap” in the CDISC website and following several links to REDCap

\*Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey

JMIR Med Inform 2022;10(1):e30363

\*\*Making Clinical Data Acquisition Standards Harmonization (CDASH) Electronic Case Report Forms Available on the REDCap Shared Data Instrument Library

J Soc Clin Data Manag. 2022 ; 2(3): . doi:10.47912/jscdm.172

## Details of the Case Study





# Details of the Case Study

“Does an agent positively affect human physical performance during exercise under induced hypoxia?”


- Phase 1 healthy volunteer study
- Out of 96 total screened, 19 treated subjects were followed over 6 weeks
- Performed at a major clinic in the USA
- Potential applications for pilots, mountaineers, military, etc.

Site Investigator downloaded “free software” and proceeded to build a study

- The software was REDCap
- The investigator tried
- Data was ugly

PROMETRIKA enlisted to map the data into SDTM after the study finished

## Mapping the Data



# Mapping the Data: Methods/Tools for Mapping

- R package: REDcap2SDTM
  - Requires embedding domain name, variable name, and test code in the REDCap field annotation in the form
    - Not feasible for this study
- Import forms into other systems that can “export” into SDTM
  - Some data appeared to have been pulled directly from EHR, so no form
  - No budget to re-enter the data
  - Still would require post processing
- Manual mapping
  - Roll up sleeves and dive in



# Mapping the Data: Exported Data File Structure - 2

## • Excel Spreadsheets (cont.)

- “ALL” spreadsheet contains all the data (640 columns x 519 rows for this study)
  - Lesson Learned: Use this file
    - Contains form data and pulls from EHR
    - Contains survey completion dates

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
1	record_id	redcap_event_name	redcap_repeat_instrument	redcap_repeat_instance	redcap_survey_identifier	screening_form_timestamp	dob	age	gender	race_1	race_2	race_3	race_4	race_5	race_6	ethnicity	height_self_reported	weight_self_reported
2	5	screening_and_opti_arm_1				5/24/2022 15:23	6/7/1978		1	0	0	0	0	0	1	2	6'5"	215
3	5	visit_1_arm_1																
4	5	visit_3_arm_1																
5	5	screening_and_opti_arm_1	protocol_deviation_form	1														
6	5	visit_1_arm_1	vitals	1														
7	5	visit_1_arm_1	urine_pregnancy_test	1														

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
1	Record ID	Event Name	Repeat Instrument	Repeat Instance	Survey Identifier	Survey Timestamp	Date of Birth:	Age	Gender:	Race (choice=American Indian)	Race (choice=Alaska Native)	Race (choice=Asian)	Race (choice=Black or African American)	Race (choice=Blacks or Other Pacific Islander)	Race (choice=White)	Ethnicity	Height: (self-reported)	Weight: (self-reported)
2	5	Screening and Optional Forms (Arm 1: Phase 1)				5/24/2022 15:23	6/7/1978		Male	Unchecked	Unchecked	Unchecked	Unchecked	Unchecked	Checked	Non Hispanic/Latino	6'5"	215
3	5	Visit #1 (Arm 1: Phase 1)																
4	5	Visit #3 (Arm 1: Phase 1)																
5	5	Screening and Optional Forms (Arm 1: Phase 1)	Protocol Deviation Form	1														
6	5	Visit #1 (Arm 1: Phase 1)	Vitals	1														
7	5	Visit #1 (Arm 1: Phase 1)	Urine Pregnancy Test	1														



# Mapping the Data: SAS Data File Structure

- Challenging to reconcile Excel columns and SAS variables
  - Long variable names don't convert well
  - Hard to correlate variables with form questions
  - Solution: create Excel version of SAS Proc Contents and annotate

Variables in Creation Order									
#	Variable	Type	Len	Format	Informat	Label	Comments		
241							DOMAIN	TESTCD	TEST
242	215 ORDER_OF_EXERCISE_TRIALS_	Char	14	\$14.00	\$14.00	Order of Exercise Trials:	SUPPLB		
243	216 VAR216	Num	8	BEST.		Power Output @ RER = 1.0 (W):	SUPPLB		
244	217 VAR217	Num	8	BEST.		Baseline 2,3-DPG:	LB	DPG	2,3-Diphosphoglycerate
245	218 BASELINE_ATP_	Num	8	BEST.		Baseline ATP:	LB	ATP	Adenosine Triphosphate
246	219 VAR219	Num	8	BEST.		Normoxic Cycling #1 (non-pedaling):	LB	DPG	2,3-Diphosphoglycerate
247	220 VAR220	Num	8	BEST.		Normoxic Cycling #2 (Stage 1):	LB	DPG	2,3-Diphosphoglycerate
248	221 VAR221	Num	8	BEST.		Normoxic Cycling #3 (RER 1.0):	LB	DPG	2,3-Diphosphoglycerate
249	222 VAR222	Num	8	BEST.		Normoxic Cycling #4 (Max):	LB	DPG	2,3-Diphosphoglycerate
250	223 VAR223	Num	8	BEST.		Hypoxic Cycling #1 (non-pedaling):	LB	DPG	2,3-Diphosphoglycerate
251	224 VAR224	Num	8	BEST.		Hypoxic Cycling #2 (Stage 1):	LB	DPG	2,3-Diphosphoglycerate
252	225 VAR225	Num	8	BEST.		Hypoxic Cycling #3 (RER 1.0):	LB	DPG	2,3-Diphosphoglycerate
253	226 VAR226	Num	8	BEST.		Hypoxic Cycling #4 (Max):	LB	DPG	2,3-Diphosphoglycerate
254	227 VAR227	Num	8	BEST.		Normoxic Cycling #1 (non-pedaling):_1	LB	ATP	Adenosine Triphosphate
255	228 VAR228	Num	8	BEST.		Normoxic Cycling #2 (Stage 1):_1	LB	ATP	Adenosine Triphosphate
256	229 VAR229	Num	8	BEST.		Normoxic Cycling #3 (RER 1.0):_1	LB	ATP	Adenosine Triphosphate
257	230 VAR230	Num	8	BEST.		Normoxic Cycling #4 (Max):_1	LB	ATP	Adenosine Triphosphate
258	231 VAR231	Num	8	BEST.		Hypoxic Cycling #1 (non-pedaling):_1	LB	ATP	Adenosine Triphosphate
259	232 VAR232	Num	8	BEST.		Hypoxic Cycling #2 (Stage 1):_1	LB	ATP	Adenosine Triphosphate
260	233 VAR233	Num	8	BEST.		Hypoxic Cycling #3 (RER 1.0):_1	LB	ATP	Adenosine Triphosphate
261	234 VAR234	Num	8	BEST.		Hypoxic Cycling #4 (Max):_1	LB	ATP	Adenosine Triphosphate
262	235 COMPLETE__13	Char	10	\$10.00	\$10.00	Complete?_13			

# Mapping the Data: SAS Data File Structure - 2

25	Variables in Creation Order												
26	# Variable			Type	Len	Format	Informat	Label	Comments				
288									DOMAI	TESTCD	TEST		
289	261	_21_O2_REST_FOREARM_BLOOD_FLOW		Num	8	BEST.		21% O2- Rest Forearm Blood Flow	CV	BLDFLRT	Blood Flow Rate		
290	262	_15_O2_REST_FOREARM_BLOOD_FLOW		Num	8	BEST.		15% O2- Rest Forearm Blood Flow	CV	BLDFLRT	Blood Flow Rate		
291	263	_10_O2_REST_FOREARM_BLOOD_FLOW		Num	8	BEST.		10% O2- Rest Forearm Blood Flow	CV	BLDFLRT	Blood Flow Rate		
292	264	VAR264		Num	8	BEST.		21% O2- 10%MVC Forearm Blood Flow	CV	BLDFLRT	Blood Flow Rate		
293	265	VAR265		Num	8	BEST.		15% O2- 10%MVC Forearm Blood Flow	CV	BLDFLRT	Blood Flow Rate		
294	266	VAR266		Num	8	BEST.		10% O2- 10%MVC Forearm Blood Flow	CV	BLDFLRT	Blood Flow Rate		
295	267	VAR267		Num	8	BEST.		21% O2- 20%MVC Forearm Blood Flow	CV	BLDFLRT	Blood Flow Rate		
296	268	VAR268		Num	8	BEST.		15% O2- 20%MVC Forearm Blood Flow	CV	BLDFLRT	Blood Flow Rate		
297	269	VAR269		Num	8	BEST.		10% O2- 20%MVC Forearm Blood Flow	CV	BLDFLRT	Blood Flow Rate		
298	270	_21_O2_REST_BRACHIAL_ARTERY_DI		Num	8	BEST.		21% O2- Rest Brachial Artery Diameter	CV	DIAMETER	Diameter		
299	271	_15_O2_REST_BRACHIAL_ARTERY_DI		Num	8	BEST.		15% O2- Rest Brachial Artery Diameter	CV	DIAMETER	Diameter		
300	272	_10_O2_REST_BRACHIAL_ARTERY_DI		Num	8	BEST.		10% O2- Rest Brachial Artery Diameter	CV	DIAMETER	Diameter		
301	273	VAR273		Num	8	BEST.		21% O2- 10%MVC Brachial Artery Diameter	CV	DIAMETER	Diameter		
302	274	VAR274		Num	8	BEST.		15% O2- 10%MVC Brachial Artery Diameter	CV	DIAMETER	Diameter		
303	275	VAR275		Num	8	BEST.		10% O2- 10%MVC Brachial Artery Diameter	CV	DIAMETER	Diameter		
304	276	VAR276		Num	8	BEST.		21% O2- 20%MVC Brachial Artery Diameter	CV	DIAMETER	Diameter		
305	277	VAR277		Num	8	BEST.		15% O2- 20%MVC Brachial Artery Diameter	CV	DIAMETER	Diameter		
306	278	VAR278		Num	8	BEST.		10% O2- 20%MVC Brachial Artery Diameter	CV	DIAMETER	Diameter		
307	279	_21_O2_REST_HEART_RATE		Num	8	BEST.		21% O2- Rest Heart Rate	VS	HR	Heart Rate		
308	280	_15_O2_REST_HEART_RATE		Num	8	BEST.		15% O2- Rest Heart Rate	VS	HR	Heart Rate		
309	281	_10_O2_REST_HEART_RATE		Num	8	BEST.		10% O2- Rest Heart Rate	VS	HR	Heart Rate		
310	282	VAR282		Num	8	BEST.		21% O2- 10%MVC Heart Rate	VS	HR	Heart Rate		
311	283	VAR283		Num	8	BEST.		15% O2- 10%MVC Heart Rate	VS	HR	Heart Rate		

# Mapping the Data: The aCRF

- Extremely dense 33 page CRF
- No CDASH type forms used
- Annotation challenges
  - Not much room for annotations
  - One page mapped to 7 domains
- Categorizing the data
  - Unexpected/Unusual domains
    - AG – CO administered to induce Hypoxia
    - CV – Blood Flow Rate, Cardiac Output, Diameter, Peak Envelope and Power Output
    - FA – Headache: frequency and types
    - FT – Left and right elbow range of motion tests
    - MB – Hepatitis, HIV and COVID
    - PR – Catheter and IV placement and blood donation
    - RE – Oxygen consumption
    - SC – Dominant hand

## Research Study Initial Screening Form

Please complete the survey below.

**DM (Demographics)**

**QS (Questionnaires)**

**VS (Vital Signs)**

**VS CAT - INITIAL SCREENING**

Last Name: \_\_\_\_\_  
 First Name: \_\_\_\_\_ [NOT SUBMITTED]  
 Middle Initial: \_\_\_\_\_

### Contact Information

Street Address: \_\_\_\_\_ [NOT SUBMITTED]  
 City: \_\_\_\_\_  
 State: \_\_\_\_\_ [NOT SUBMITTED]  
 Zip Code: \_\_\_\_\_  
 Phone Number: \_\_\_\_\_  
 Email Address: \_\_\_\_\_ [NOT SUBMITTED]  
 Clinic # \_\_\_\_\_

Sex: \_\_\_\_\_ [SEX]  
 Date of Birth: \_\_\_\_\_ [BIRTHDTG]

Age: \_\_\_\_\_ [AGE] [AGEU - YEARS]

VSORRES when VSTESTCD = HEIGHT

VSORRES when VSTESTCD = WEIGHT

Height (feet and inches): \_\_\_\_\_ Weight (pounds): \_\_\_\_\_

Race: \_\_\_\_\_ [RACE] Ethnicity: \_\_\_\_\_ [ETHNIC]

SUPPOM.OVAL when QNAM = CRACE1 - CRACE3  
 [RACE = MULTIPLE when multiple values are selected, and individual responses are in SUPPOM.OVAL when QNAM = RACE1 - RACE3]

VS CAT - SCREENING QUESTIONNAIRE

How did you become aware of the study?

VSORRES when QSTESTCD = SCRN01B

VSORRES when QSTESTCD = SCRN01A

VSORRES when QSTESTCD = SCRN01B

VSORRES when QSTESTCD = SCRN01C

VSORRES when QSTESTCD = SCRN01D

VSORRES when QSTESTCD = SCRN01E

Other

VSORRES when QSTESTCD = SCRN01F

Are you currently enrolled in any other studies?

☐ Yes

☐ No

VSORRES when QSTESTCD = SCRN02

Completion date of last study, if applicable?

VSORRES when QSTESTCD = SCRN03

Dates of future studies, if applicable (mm/dd/yyyy):  
 (enter all future dates with a comma between dates)

VSORRES when QSTESTCD = SCRN04

Do you exercise on a regular basis?

☐ Yes

☐ No

VSORRES when QSTESTCD = SCRN05

What is your most common mode of exercise?

VSORRES when QSTESTCD = SCRN06

How many days per week do you take part in structured exercise?

VSORRES when QSTESTCD = SCRN07

On average, how many minutes per day do you exercise?

VSORRES when QSTESTCD = SCRN08

What intensity is the exercise that you normally take part in?  
 (check all that apply)

☐ Light

☐ Moderate

☐ High

VSORRES when QSTESTCD = SCRN09A

VSORRES when QSTESTCD = SCRN09B

VSORRES when QSTESTCD = SCRN09C

09/19/2023 2:30am

projectredcap.org

REDCap

SUPPMH.QVAL when QNAM = MHSLPDX

☐ Yes    PROCUR when PRTRT = SURGICAL  
☐ No      HISTORY

SUPPPR.QVAL when QNAM = PRSRGDC

☐ Yes ☒ No MHOCCUR when MHTERM = HEADACHE

One

☐ Less than 1 per month

☐ 2 to 4 per month

<input type="checkbox"/> Throbbing	FAORRES when FATESTCD = THROB
<input type="checkbox"/> Dull	FAORRES when FATESTCD = DULL
<input type="checkbox"/> Sharp	FAORRES when FATESTCD = SHARP
<input type="checkbox"/> Tight band	FAORRES when FATESTCD = TIGHTBND
<input type="checkbox"/> Burning	FAORRES when FATESTCD = BURN
<input type="checkbox"/> Stabbing	FAORRES when FATESTCD = STAB

☐ Yes ☒ No MHOCCUR when MHTERM = BACK PAIN

SUPPMH.QVAL when QNAM = MHBPNDX

☐ Yes ☒ No SUOCCUR when SUTERM = TOBACCO

☐ Yes ☒ No SUOCCUR when SUTERM = TOBACCO

**SUDUR**

SUENDTC

☐ Yes ☒ No

☐ Yes ☒ No

CMTRT

☐ Left **SCORES when SCTESTCD = HANDDOM**

☐ Yes

☐ No **OSORRES when OSTESTCD = SCRN01**

☐ Yes

☐ No **OSORRES when OSTESTCD = SCRN01**

PR (Procedures)

### FT (Functional Tests)

### RE (Respiratory System Findings)

Data Entered By: [NOT SUBMITTED]

Sex: \_\_\_\_\_

SEX

**LBCAT - EXERCISE DATA**

Pregnancy Test: LBTESTCD - HCG

Date of Birth:

ARTIFICIAL

VSORRES when VSTESTCD = HEIGHT		VSORRESU = cm	VSOCAD = EXERCISE DATA	
VSORRES when VSTESTCD = WEIGHT		VSORRESU = kg	VSOCAD = EXERCISE DATA	
VSORRES when VSTESTCD = BMI		VSORRESU = kg/m <sup>2</sup>	VSOCAD = EXERCISE DATA	
VSORRES when VSTESTCD = SYSP		VSORRESU = mmHg	VSOCAD = EXERCISE DATA	
VSORRES when VSTESTCD = DIABP		VSORRESU = mmHg	VSOCAD = EXERCISE DATA	
Height (cm): _____ Weight (kg): _____ BMI (kg/m <sup>2</sup> ): _____				
Vital Signs				
SBP (mmHg): _____		VSORRES when VSTESTCD = MAP	VSORRESU = mmHg	
DBP (mmHg): _____		VSORRES when VSTESTCD = PULSE	VSORRESU = beats/min	
Heart Rate (BPM): _____		VSORRES when VSTESTCD = TEMP	VSORRESU = C	
Body Temperature (°C): _____				

Instrumentation and Study Preparation		Arterial Line Placement:		Time:	
PRTRT	Retrograde IV Placement:	Time:	PRTRT	PRTRT	PRTRT

Maximal Voluntary Contractions: **FTDTC** **ETCAT - EXERCISE DATA**

Right Arm: 10 FTORRES when ETTESTED = PUL0224

Left Arm: \_\_\_\_\_ kg **FTORRES when FTTESTCD = PUL0225**

\*Note: these values are the average of 3 MVCs from each arm



## LB (Laboratory Test Results)

## VS (Vital Signs)

Page 19

LBORRESU

Handgrip Exercise- Blood Gases Inspirate Intensity PaO2  
(mmHg) aChb  
(g/dL) SaO2  
(%) PvO2  
(mmHg) vChb  
(g/dL) SvO2  
(%)

21% O2 Rest  
21% O2 10%MVC  
21% O2 20%MVC  
15% O2 Rest  
15% O2 10%MVC  
15% O2 20%MVC  
10% O2 Rest  
10% O2 10%MVC  
10% O2 20%MVC

Handgrip- Ultrasound Data Inspirate Intensity Peak vBF (cm/s) BA Diameter (cm) MAP (mmHg) Heart Rate (bpm) Peak TCD (cm/s)  
21% O2 Rest  
21% O2 10%MVC  
21% O2 20%MVC  
15% O2 Rest  
15% O2 10%MVC  
15% O2 20%MVC  
10% O2 Rest  
10% O2 10%MVC  
10% O2 20%MVC

Handgrip- NIRS Data NIRS on Forearm Forehead NIRS  
Inspirate Intensity Deoxy (uM) Oxy (uM) Total (uM) StO2 (%) Deoxy (uM) Oxy (uM) Total (uM) StO2 (%)  
21% O2 Rest  
21% O2 10%MVC  
21% O2 20%MVC  
15% O2 Rest  
15% O2 10%MVC  
15% O2 20%MVC  
10% O2 Rest  
10% O2 10%MVC  
10% O2 20%MVC

## RE (Respiratory System Findings)

## CV (Cardiovascular System Findings)

LBSCAT = REST LBGRPID = HANDGRIP  
LBSCAT = 10% MAXIMAL VOLUNTARY CONTRACTIONS  
LBSCAT = 20% MAXIMAL VOLUNTARY CONTRACTIONS

LBORRES when LBTESTCD = PCO2  
LBORRES when LBTESTCD = PCO2  
LBORRES when LBTESTCD = SAO2FIO2  
LBORRES when LBTESTCD = PvO2  
LBORRES when LBTESTCD = HGB  
LBORRES when LBTESTCD = SAO2FIO2

LBORRES when LBTESTCD = PCO2  
LBORRES when LBTESTCD = PCO2  
LBORRES when LBTESTCD = SAO2FIO2  
LBORRES when LBTESTCD = PvO2  
LBORRES when LBTESTCD = HGB  
LBORRES when LBTESTCD = SAO2FIO2

LBORRES when LBTESTCD = HGBDOXY  
LBORRES when LBTESTCD = HGBDOXY  
LBORRES when LBTESTCD = HGB  
LBORRES when LBTESTCD = SAO2FIO2  
LBORRES when LBTESTCD = HGBDOXY  
LBORRES when LBTESTCD = HGBDOXY  
LBORRES when LBTESTCD = HGB  
LBORRES when LBTESTCD = SAO2FIO2

Abbreviations: PaO2, arterial oxygen tension; aChb, arterial hemoglobin concentration; SaO2, arterial oxygen saturation; PvO2, venous oxygen tension; vChb, venous hemoglobin concentration; SvO2, venous oxygen saturation; MVC, maximal voluntary contraction; vBF, mean blood flow velocity; BA, brachial artery

Cycling Exercise Inspirate Order:

Inspirate Intensity PaO2

(mmHg) PaCO2

(mmHg) cHb

(g/dL) SaO2

(% Lactate (mmol/L) Blood Temp (°C)

21% O2 Rest

21% O2 Max

15% O2 Rest

15% O2 Max

Inspirate Intensity Power Output (W) VO2 (l/min) Heart Rate (bpm) TCD Peak Envelope (cm/s) Cardiac Output (l/min)

21% O2 Rest

21% O2 Max

15% O2 Rest

15% O2 Max

NIRS on Vastus Lateralis NIRS on Forehead

Inspirate Intensity Deoxy (uM) Oxy (uM) Total (uM) StO2 (%) Deoxy (uM) Oxy (uM) Total (uM) StO2 (%)

21% O2 Rest

21% O2 Max

15% O2 Rest

15% O2 Max

09/19/2023 2:30am

projectredcap.org

REDCap

## Blood Volume (CO Rebreathe)

## AG (Procedure Agents)

## LB (Laboratory Test Results)

Page 20

Please complete the survey below.

Thank you!

LBSCAT = CARBON MONOXIDE REBREATHE

LBSCAT = CARBON MONOXIDE REBREATHE

119) Volume of CO administered (mL) AGDOSU

AGDOSE

49.7

58.9

68.0

77.6

86.7

95.3

105.9

115.6

123.5

133.5

120) CO remaining in system after rebreath

SUPPAG\_QVAL when QNAM = COREMAIN

121) Hb-CO pre: LBTPPT = PRE

LBORRES

122) Hb-CO post: LBTPPT = POST

LBORRES

123) Hb-CO post 5-mins post rebreath: LBTPPT = 5 MIN POST

LBORRES

LBTESTCD = CARBXHGB

LBTESTCD = CARBXHGB

# Mapping the Data: Specifications and Programming

- Mapping to Controlled Terminology (CT) challenges
  - Parsing out CM term, dose, unit, route, frequency and indication from comment style free text
  - Determining decodes of values required looking at both the Raw and Label tabs
- Data issues and challenges
  - Identifying the visit for a row sometimes had to be based on the data points that were present
  - Data was locked and final, so no corrections possible
    - A fair amount of existing data issues
    - Very helpful to only have to spec for the data that was present
    - Height data was sometimes converted to a partial date when exporting into Excel
      - Documented conversion correction in csdrg.pdf

Reported Height in EDC	Reported Height in Excel	Reported Height in SAS	Converted Height in SAS
5-9	9-May	45421	5' 9"

# Mapping the Data: Specifications and Programming - 2

- Data issues and challenges (cont.)
  - AE information collected in two different forms that needed to be merged together
    - Adverse Event Report
      - Date treatment drug started: incomplete
      - End date: all blank
    - Adverse Event Reconciliation
      - Diagnosis contained Preferred Term
      - Predominant Symptom: redundant
      - Resolution: only resolved or ongoing
      - Please specify: all blank

**Adverse Event Report**

**AE (Adverse Events)**  
**DM (Demographics)**

Page 25

Patient Name: [screening\_and\_opti\_arm\_2][last\_name], [screening\_and\_opti\_arm\_2][first\_name]  
Clinic #: [screening\_and\_opti\_arm\_2][mcnumber]  
Date of Birth: [screening\_and\_opti\_arm\_2][dob]

This form is to be filled out by the study staff member that is in direct contact with the patient. Following the completion of this form, an auto-generated email will be set to the investigators to complete the reconciliation form, and reach back out to the participant with the appropriate course of action.

Adverse Events should be reported from first dose through 28 days post last dose. Only SAEs related to study-mandated procedures need to be captured on the AE page between Informed Consent and first dose. All others should be captured as Medical History.

Did the patient experience any adverse events? ☐ Yes ☒ No  
[NOT SUBMITTED]

Date treatment drug started: [NOT SUBMITTED]

Start Date of the Adverse Event: [AESTDTC]

Describe the adverse event in detail: (include location, intensity, duration, etc)  
[AETERM first 200 characters]  
[SUPPAE QVAL when QNAM = AETERM1 next 200 characters]

Were any over-the-counter medications taken to treat the AE?  
☒ Yes ☐ No  
(If yes, please fill out a concomitant medication form.)  
[AECONTNT] [SUPPAE QVAL when QNAM = AETOCMD]

Is the adverse event still ongoing?  
☒ Yes ☐ No  
[AEBNRPPT - ONGOING when Yes] [SUPPAE QVAL when QNAM = AEBONGC]

When did the adverse event end?  
[NOT SUBMITTED]

Outcome of adverse event:  
[AEBOUT] ☐ Not recovered/ not resolved  
☐ Recovered/ resolved  
☐ Recovered/ resolved with sequelae  
☐ Unknown/ Lost to follow-up

Was the adverse event serious?  
[AESER] ☐ Yes ☒ No

Serious Adverse Event Outcome:  
[AESDTH] ☐ Death [DTHFL-Y]  
[AESDISAB] ☐ Life threatening [AESDIFE]  
[AESDISAB] ☐ Disability or permanent damage  
[AESDISAB] ☐ Hospitalization (initial or prolonged)  
[AESDISAB] ☐ Congenital anomaly or birth defect  
[AESDIFE] ☐ Other serious (important medical event)

# Mapping the Data: Specifications and Programming - 2

- AE information collected in two different forms that needed to be merged together (cont.)

## Adverse Event Reconciliation AE (Adverse Events) Page 27

Patient Name: [screening\_and\_opti\_arm\_2][last\_name], [screening\_and\_opti\_arm\_2][first\_name]  
 Clinic # [screening\_and\_opti\_arm\_2][mcnumber] **CM (Concomitant Medications)**  
 Date of Birth: [screening\_and\_opti\_arm\_2][dob]  
**SOURCE = ADVERSE EVENT RECONCILIATION**  
 Diagnosis **AE (Adverse Events)**  
 Predominant Symptom (if applicable): **NOT SUBMITTED**  
 ACTION Study Treatment Dose: **REASON**  
☐ No action taken  
☐ Reduced  
☐ Stopped Temporarily  
☐ Permanently Discontinued  
 At whose direction? ☐ Physician  
☐ Participant did this on their own  
**SUPRAE QVAL when QNAM = ACNDR**  
 ACTION Participant: ☐ Withdrawn from the study  
☐ Corrective treatment/therapy  
☐ Other  
☐ No action taken  
 Please specify **AEACNTH**  
 Were any other concomitant medications prescribed? **AECONTRT**  
☒ Yes **SUPRAE QVAL when QNAM = AEOTHMED**  
☐ No  
**Note: Linked to related AE record via RELREC**  
 Concomitant medication #1: **CMTRT** **CMDOSE** **CMDOSTXT** **CMDOSU** **CMROUTE**  
**SUPRAE QVAL when QNAM = CONMED**  
 Concomitant medication #1 indication: **CMINDC**  
 Concomitant medication start date: **CMGTOTC**  
 Is participant still taking this medication? **CMENRPT - ONGOING, if Yes**  
☒ Yes  
☐ No  
 Concomitant medication end date: **CMENDTC**  
 Concomitant medication #2: **CMTRT** **CMDOSE** **CMDOSTXT** **CMDOSU** **CMROUTE**  
**SUPRAE QVAL when QNAM = CONMED**  
 Concomitant medication #2 indication: **CMINDC**  
 Concomitant medication start date: **CMGTOTC**

## AE (Adverse Events) CM (Concomitant Medications) DM (Demographics) Page 28

**AE (Adverse Events)** **CM (Concomitant Medications)** **DM (Demographics)**  
**SEE PAGE 27**  
 Is participant still taking this medication? **CMENRPT - ONGOING, if Yes**  
☒ Yes  
☐ No  
 Concomitant medication end date: **CMENDTC**  
 RESOLUTION Did the AE resolve? **NOT SUBMITTED**  
☐ Unknown  
☐ No - still continuing at the end of study  
☐ Resolved  
☐ Continues resolving  
☐ Continuing but stable  
☐ Worsening  
☐ Other  
 AE Severity: **AETOXGR**  
☐ Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.  
☐ Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL\*.  
☐ Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL\*.  
☐ Grade 4: Life-threatening consequences; urgent intervention indicated.  
☐ Grade 5: Death related to AE  
 Please specify: **NOT SUBMITTED**  
 Date of Resolution **AEENDTC** **AEENDTC**  
 RELATIONSHIP TO STUDY DRUG Is there a reasonable possibility that the AE is related to FT-4202? **AEREL**  
☐ Unknown  
☐ Not Related  
☐ Unlikely  
☐ Possible  
☐ Probably/Likely  
☐ Definitely  
**SUPRAE QVAL when QNAM = AERELC**  
 RELATIONSHIP TO STUDY PROCEDURES Is there a reasonable possibility that the AE is related to participation in the study procedures? **AERELNDT**  
☐ Unknown  
☐ Not Related  
☐ Unlikely  
☐ Possible  
☐ Probably/Likely  
☐ Definitely  
 Comments (include follow-up information) **SUPRAE QVAL when QNAM = AECONTH**  
 Name of staff member collecting initial data: **NOT SUBMITTED**  
 Date: **NOT SUBMITTED**



# Mapping the Data: Specifications and Programming - 3

- Additional data added later
  - Missing lab data was provided in a separate Excel spreadsheet
- Usual clinical trial data that was missing
  - Informed Consent Date not captured in REDCap for all subjects
    - Documented in csdrg.pdf
  - Actual date/time of first dose
    - Derived from date of last dose (which was assigned from a lab date)
  - Failed Inclusion/Exclusion Criteria (IE not created)
    - Detailed “Screening Questionnaire” instead
  - Most units and methods were not included in the data
    - Assigned from text in the form, variable label or protocol

# Mapping the Data: Specifications and Programming - 4

- Usual clinical trial data that was missing (cont.)
  - Sex and Age for some subjects
  - Lab ranges were imbedded in a lengthy Word document
    - Added as an appendix to csdrg.pdf
  - Dates for when some events happened were not collected
    - The ALL file contained survey completion dates that could be leveraged, in some cases
      - PROMIS Questionnaire was filled out at the site by the subject (confirmed with the site)
  - Only the Preferred Term medical coding term for AEs and CMs was provided in the data
    - Versions of dictionaries used to code were not available
    - Request to “programmatically merge” the missing information from the dictionaries was not feasible
    - Used an external coding tool to completely code the terms

# Mapping the Data: Specifications and Programming - 5

- Use of “look up” tabs to assist in programming
  - CMTERM from three different forms

medsupplementslist	group_	term_	dose_	units_	route_	freq_	indic_
Birth control	MED1	Birth control					
Claritin D	MED2	Claritin D					
Clobetasol propionate (topical steroid)	MED3	Clobetasol propionate (topical steroid)			TOPICAL		
Daily multi-vitamin	MED4	Multi-vitamin				QD	
Daily multi-vitamins, phexofenadine (seasonal allergies)	MED5	Multi-vitamin				QD	
Daily multi-vitamins, phexofenadine (seasonal allergies)	MED5	Phexofenadine					SEASONAL ALLERGIES

birthcontrol_type	term_	dose_	units_
Aviane 0.1mg/0.02mg	Aviane	0.1/0.02	mg
Estrogen progesterone pill	Estrogen progesterone		PILL
Ethinylestradiol + Gestodene (Gynera)	Ethinylestradiol and Gestodene (Gynera)		

concomitant_medication__1_	term_	dose_	units_	route_
human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine Injectable Product	human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine Injectable Product			
ibuprofen 200 MG Oral Tablet [Advil]	Advil	200	mg	Oral

# Mapping the Data: Specifications and Programming - 6

- Use of “look up” tabs to assist in programming (cont.)
  - CVTEST

Source		Target							
Filename	Variable Name	CVCAT	CVSCAT	CVTESTCD	CVTEST	CVORRESU	CVMETHOD	CVLOC	CVGRPID
ALL_L	21_O2_REST_TCD_PEAK_ENVELOPE	21% OXYGEN	REST	PENVEL	Peak Envelope	cm/s	TRANSCRANIAL DOPPLER ULTRASOUND	SKULL	HANDGRIP EXERCISE
ALL_L	VAR289	21% OXYGEN	10% MAXIMAL VOLUNTARY CONTRACTION	PENVEL	Peak Envelope	cm/s	TRANSCRANIAL DOPPLER ULTRASOUND	SKULL	HANDGRIP EXERCISE
ALL_L	VAR290	21% OXYGEN	20% MAXIMAL VOLUNTARY CONTRACTION	PENVEL	Peak Envelope	cm/s	TRANSCRANIAL DOPPLER ULTRASOUND	SKULL	HANDGRIP EXERCISE
ALL_L	15_O2_REST_TCD_PEAK_ENVELOPE	15% OXYGEN	REST	PENVEL	Peak Envelope	cm/s	TRANSCRANIAL DOPPLER ULTRASOUND	SKULL	HANDGRIP EXERCISE
ALL_L	VAR292	15% OXYGEN	10% MAXIMAL VOLUNTARY CONTRACTION	PENVEL	Peak Envelope	cm/s	TRANSCRANIAL DOPPLER ULTRASOUND	SKULL	HANDGRIP EXERCISE
ALL_L	VAR293	15% OXYGEN	20% MAXIMAL VOLUNTARY CONTRACTION	PENVEL	Peak Envelope	cm/s	TRANSCRANIAL DOPPLER ULTRASOUND	SKULL	HANDGRIP EXERCISE
ALL_L	10_O2_REST_TCD_PEAK_ENVELOPE	10% OXYGEN	REST	PENVEL	Peak Envelope	cm/s	TRANSCRANIAL DOPPLER ULTRASOUND	SKULL	HANDGRIP EXERCISE
ALL_L	VAR295	10% OXYGEN	10% MAXIMAL VOLUNTARY CONTRACTION	PENVEL	Peak Envelope	cm/s	TRANSCRANIAL DOPPLER ULTRASOUND	SKULL	HANDGRIP EXERCISE
ALL_L	VAR296	10% OXYGEN	20% MAXIMAL VOLUNTARY CONTRACTION	PENVEL	Peak Envelope	cm/s	TRANSCRANIAL DOPPLER ULTRASOUND	SKULL	HANDGRIP EXERCISE

- Clear, detailed specifications made the programming go relatively quickly
  - Used two SDTM SME's with advanced SAS programming skills

# Mapping the Data: Define and SDRG

- Define creation went smoothly, thanks to the clear specifications
- Data oddities and mapping issues were noted in the csdrg.pdf

## 3.4.11 EX – Exposure

The actual dates of exposure were not collected, so the EC domain was not created, since it would be exactly the same as the EX domain. The P50OXYGN lab test was collected on the same day that the last dose of study drug was taken, so that date is used as the last study drug dose date and then 6 days is subtracted from it to derive the first study drug dose date.

## 3.4.14 LB – Laboratory Test Results

Normal ranges were not captured in EDC but were made available within a separate document that is included here as [Appendix II](#).

- Final mapping resulted in a relatively low number of Pinnacle 21 issues
  - Most were data value related
  - The mapping strategy worked!

# Conclusions



# Conclusions

- Data from REDCap can successfully be mapped into SDTM manually
  - Requires deep understanding of SDTM standards and the collected data (and patience)
  - May only be possible by a limited number of organizations
- Outreach is potentially needed to ensure that REDCap users are aware of:
  - The existence of CDASH forms and what they are
  - Standards in general to make the process easier
    - REDCap documentation could be updated to mention CDASH forms
    - Sponsors working with academic institutions could provide guidance through:
      - Standards leads
      - CDASH/SDTM SMEs
    - CDISC avenues for promoting
      - CAC member outreach
      - More press
      - More presentations at related conferences



## Thank You:

For listening!

To my colleague Elena Prosekova for her expertise and good humor in helping complete this study mapping

Contact information:

Susan Mutter, Director, Statistical Programming

PROMETRIKA, LLC

[smutter@prometrika.com](mailto:smutter@prometrika.com)

1-617-844-0202

